Charlotte, NC (PRWEB) December 12, 2014
SonaCare Medical, a leading manufacturer of medical High Intensity Focused Ultrasound (HIFU) devices, announced today that five new members have been selected to serve on the company’s Board of Directors. The new members bring additional health care industry experience to the Board and include a physician and hospital CEO, a president of multiple medical companies, two founders of investment firms, and SonaCare Medical’s newly appointed CEO. The new Board members are Evan Bakst, Dr. Mark Carol, David Koslosky, Dr. Bruce Murphy, and Dr. John Wilkerson. They join the Chairman of the Board, Thomas Mendell, along with Co-Founder and Board Member, Stephen Puckett, Sr.
Mr. Evan Bakst is the Founder and Portfolio Manager of Treetop Capital, a fundamental, value-oriented, friendly activist fund focused primarily on small to mid-cap companies. Before launching Treetop, Mr. Bakst held several executive and leadership positions at JP Morgan and The Beacon Group. He also draws on strategic and operational expertise from his time as a consultant at Bain and Company. Mr. Bakst earned a Bachelor of Arts in Economics from the University of California, Berkeley, and an M.B.A. from the Harvard Graduate School of Business Administration.
Dr. Mark Carol, SonaCare Medical’s current CEO, is a neurosurgeon with over 30 years of experience in medical device and health care services in publicly traded and privately held companies. Widely viewed as the "father of IMRT" and a household name in Radiation Oncology, he has a proven track record of taking nascent disruptive technology, in multiple disparate fields, from conceptualization through commercialization. Dr. Carol earned a BS from Amherst College where he graduated Magna Cum Laude and an MD with Distinction in Research from the University of Rochester. Dr. Carol completed his residency in neurosurgery and a fellowship in neurotrauma at the University of Maryland. He also spent time in the graduate program in artificial intelligence at the University of Massachusetts, and is an Adjuvant Assistant Professor of Radiation Oncology at Brown University.
Mr. David Koslosky is the owner of Prime Healthcare Solutions, a company that provides telemedicine solutions, as well as President of two medical marketing companies: Avalon Medical and JDK Medical. Mr. Koslosky has accrued more than 20 years experience in medical device and operating room sales, winning numerous performance and excellence awards. Mr. Koslosky received a Bachelor of Science in Mathematics from Bloomsburg University of Pennsylvania, with a focus on business statistics and computer science.
Dr. Bruce Murphy is the President and CEO of Arkansas Heart Hospital. He is a physician who is board-certified in internal medicine, cardiovascular disease and interventional cardiology. In addition, Dr. Murphy earned a Ph.D. in Pharmacology. In addition to his private practice at Little Rock Cardiology Clinic, he was the Medical Director at Arkansas Heart Hospital, President of Little Rock Cardiology Clinic, and Assistant Professor of Medical Sciences at University of Arkansas.
Dr. John Wilkerson is a Founder and Senior Advisor of venture capital firm Galen Partners. Dr. Wilkerson currently serves on the Board of Directors of several of Galen’s privately held portfolio companies as well as Quotient Diagnostics, a public company. Dr. Wilkerson is the immediate past Chairman of Atlantic Health Systems, a New Jersey hospital system, is a trustee and former President of the Museum of American Folk Art and Founder of the E. L. Rose Conservancy. He earned a Ph.D. from Cornell University and is a member of the Cornell University Council and immediate past Chairman of the College of Agricultural and Life Sciences advisory board.
SonaCare Medical’s Chairman of the Board, Thomas Mendell, welcomed the new additions. “Serving on the Board requires dedication, time, and a commitment to bringing state-of-the-art medical technology to cancer patients and their physicians around the world. We appreciate the talent and time the leaving Board Members provided to SonaCare Medical and welcome the new Members as they dive in to make a positive impact on patient’s quality of life through the treatment options enabled by SonaCare’s HIFU devices.”
About SonaCare Medical
SonaCare Medical, a privately held, venture-backed healthcare company is a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies. SonaCare Medical is committed to developing technologies for urological indications that offer precise and innovative procedures that can control cancer and reduce potential quality of life altering side effects. SonaCare Medical, with its subsidiary Focus Surgery, Inc., designs and manufactures high intensity focused ultrasound (HIFU) medical devices, including the following: Sonablate® 450 which is investigational in the U.S. and being studied in a pivotal FDA clinical trial as a possible treatment for recurrent prostate cancer in patients treated previously with external beam radiation therapy; Sonablate® 500, which has CE Marking and is, or has been, approved for use to treat prostate cancer in more than 30 countries outside the U.S.; and Sonatherm® laparoscopic HIFU surgical ablation system which is 510(k) cleared in the U.S. The FDA has made no decision as to the safety or efficacy of Sonablate® 450 or 500. In the event Sonablate® 450 is approved by the FDA for use in the U.S., there is no assurance that instructions for use or the specifications of the device will be the same for treatment approved or authorized in other countries outside of the U.S. SonaCare Medical was founded in 2004 and is headquartered in Charlotte, N.C.
For additional information, visit http://www.SonaCareMedical.com